Abstract:The emerging clinical success of checkpoint blockade immunotherapy in human cancer patients has highlighted the critical importance of PD-L1, a ligand for the T cell inhibitory receptor PD-1, as a molecular target in cancer immunotherapy. PD-L1 is constitutively expressed in tumor cells and is also inducible by inflammatory cytokines such as IFNgamma. It has been proposed that tumor cells may sense the elevated IFNgamma from activated host T cells as a “threat” in the tumor microenvironment and adapt it by up-regulating PD-L1. The aim of this study is to elucidate the molecular mechanism underlying IFNgamma regulation of PD-L1 expression in tumor cells. We observed that PD-L1 is constitutively expressed, albeit at low level, in multiple types of cancer cells, including pancreatic, colon, breast, and sarcoma cells. IFNgamma treatment dramatically increased PD-L1 expression level and IFNgamma up-regulates PD-L1 expression through the Jak-STAT1 signaling pathway in vitro and in vivo. Chromatin immunoprecipitation assay did not identify IFNgamma-activated pSTAT1 binding to the pd-l1 promoter. Instead, we observed that IFNgamma activates IRF1 transcription and IRF1 is required for IFNgamma-induced PD-L1 expression. Chromatin immunoprecipitation analysis shows that pSTAT1 is associated with the irf1 but not the pd-l1 promoter. Analysis of the irf1 promoter DNA sequence revealed a pSTAT1-binding consensus sequence, and electrophoretic mobility shift assay indicates that pSTAT1 directly binds to this DNA element of the irf1 promoter. Furthermore, we demonstrated that IRF1 is associated with the pd-l1 promoter chromatin near the irf1 transcription initiation site. The pd-l1 promoter region contains a putative IRF1-binding consensus sequence and electrophoretic mobility shift assay shows that IRF1 binds to this DNA element of the pd-l1 promoter region. Taken together, our data indicate that IFNgamma activates pSTAT1 that binds to the irf1 promoter to activate irf1 transcription. IFNgamma-induced IRF1 then binds to the pd-l1 promoter to activate pd-l1 transcription in tumor cells. Citation Format: Chunwan Lu, Amy V. Paschall, Priscilla S. Redd, Iryna Lebedyeva, Kebin Liu. IFNgamma regulates PD-L1 expression through activating IRF1 transcription in tumor cells. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2327.

Abstract B86: the NF-κB P65 and P50 Homodimer Cooperate with Pstat1 to Synergistically Activate Inos Transcription

The NF-κB P65 and P50 Homodimer Cooperate with Pstat1 to Synergistically Activate Inos Transcription in Cancer Cells and Myeloid Cells (INM1P.440)

The NF-κB p65 and p50 homodimer cooperate with IRF8 to activate iNOS transcription

NF-κB p105-mediated nuclear translocation of ERK is required for full activation of IFNγ-induced iNOS expression

Abstract 2327: IFNgamma Regulates PD-L1 Expression Through Activating IRF1 Transcription in Tumor Cells

Ifngamma Regulates Pd-L1 Expression Through Activating Irf1 Transcription In Tumor Cells

Epigenetic Regulation of Inflammatory NF-κB Target Genes by IFN-γ via IRF1

Selective regulation of a defined subset of inflammatory and immunoregulatory genes by an NF-{kappa}B p50-I{kappa}B{zeta} pathway

Selective Regulation of a Defined Subset of Inflammatory and Immunoregulatory Genes by an NF-κB p50-IκBζ Pathway

Investigating the Role of TNF-α and IFN-γ Activation on the Dynamics of iNOS Gene Expression in LPS Stimulated Macrophages

Abstract 568: Identification of Novel Pre-translational Regulatory Mechanisms for NF-?B Activation

IL-17 Intensifies IFN-γ-induced NOS2 Upregulation in RAW 264.7 Cells by Further Activating STAT1 and NF-κB

Abstract 2350: Type I Interferon Suppresses Tumor Growth Through Activating the STAT3-granzyme B Pathway in Tumor-Infiltrating Cytotoxic T Lymphocytes

Regulation of Inducible Nitric Oxide Synthase Expression by P300 and P50 Acetylation.

Activation of the murine interleukin-12 p40 promoter by functional interactions between NFAT and ICSBP

Transdifferentiation Requires Inos Activation

NF-kB1 induces T cell dysfunction to promote colon tumorigenesis

Peroxide-mediated Chromatin Remodelling of a Nuclear Factor Kappab Site in the Mouse Inducible Nitric Oxide Synthase Promoter

Type I Interferon Activates PD-1 Expression Through Activation of the STAT1-IRF2 Pathway in Myeloid Cells

Abstract 2353: Noncanonical NF-κB Activation Mediates STAT3-stimulated IDO Up-Regulation in Myeloid-Derived Suppressor Cells in Breast Cancer

P50 Suppresses Cytotoxic T Lymphocyte Effector Function to Regulate Tumor Immune Escape and Response to Immunotherapy.